GO Capital Fund

Rimsys is a leading provider of Regulatory Information Management (RIM) software specifically designed for medical technology companies. The software is tailored for regulatory affairs professionals, enabling them to digitize and automate compliance processes to meet evolving global regulations. Rimsys offers a comprehensive solution that manages global Unique Device Identification (UDI) requirements and facilitates the navigation of essential regulatory components, including product registration, standards management, and regulatory intelligence. By actively tracking product registrations and monitoring relevant technical files and standards, Rimsys simplifies regulatory management for clients, transforming their operations into a more organized and efficient system for teams and international partners.

LeddarTech develops advanced detection and ranging systems using infrared LEDs and algorithms. It offers off-the-shelf smart sensor modules for various applications such as traffic management, autonomous vehicles, smart homes, and agriculture. The company provides interconnected sensor solutions for infrastructure, pollution monitoring, mobility, and traffic management in cities.

WhatsNexx Moments leverages the world’s leading marketing applications, consolidating campaign management across channels and locations to build intuitive and delightful customer experiences. Our suite and solutions empower marketers to collect and integrate raw customer data into profiles and segments, to design and manage sophisticated, automated campaigns, and to visualize and optimize the customer journey in real-time - all using the tools and apps you already trust to deliver the front line experiences.

LeddarTech develops advanced detection and ranging systems using infrared LEDs and algorithms. It offers off-the-shelf smart sensor modules for various applications such as traffic management, autonomous vehicles, smart homes, and agriculture. The company provides interconnected sensor solutions for infrastructure, pollution monitoring, mobility, and traffic management in cities.

Alethia Biotherapeutics, Inc. is a biotechnology company based in Montreal, Canada, founded in 2002. It specializes in the discovery and development of monoclonal antibody-based therapeutics aimed at treating various forms of cancer, particularly focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. The company's product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the effectiveness of DNA-damaging chemotherapy agents; sCLU, a glycoprotein linked to multiple malignancies; AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases; and AB-0440, a protein involved in osteoclast differentiation associated with bone loss. Alethia Biotherapeutics employs patented STAR discovery technology to develop therapeutics that address clinically relevant disease-specific targets, thereby aiding healthcare professionals in managing cancer and its complications.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing etripamil, a rapid-onset calcium channel blocker for cardiovascular conditions. The lead product is etripamil, administered as a nasal spray for self-treatment of episodes of paroxysmal supraventricular tachycardia, with ongoing Phase III studies in the United States and Canada. The company is also advancing development for other cardiovascular indications, including atrial fibrillation and angina, with a Phase II program for atrial fibrillation with rapid ventricular response. Founded in 2003, Milestone is headquartered in Montreal.

WhatsNexx Moments leverages the world’s leading marketing applications, consolidating campaign management across channels and locations to build intuitive and delightful customer experiences. Our suite and solutions empower marketers to collect and integrate raw customer data into profiles and segments, to design and manage sophisticated, automated campaigns, and to visualize and optimize the customer journey in real-time - all using the tools and apps you already trust to deliver the front line experiences.

Neuralitic Systems specializes in mobile data intelligence technology, focusing on helping mobile service operators comprehend user behaviors that drive data service adoption. By providing insights into emerging trends and habits, the company enables operators to enhance decision-making related to subscriber acquisition, conversion, and retention. Its solutions are designed to automatically uncover new behavioral patterns, facilitating the dynamic leveraging of these insights to stimulate revenue growth within the data service sector.

Alethia Biotherapeutics, Inc. is a biotechnology company based in Montreal, Canada, founded in 2002. It specializes in the discovery and development of monoclonal antibody-based therapeutics aimed at treating various forms of cancer, particularly focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. The company's product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the effectiveness of DNA-damaging chemotherapy agents; sCLU, a glycoprotein linked to multiple malignancies; AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases; and AB-0440, a protein involved in osteoclast differentiation associated with bone loss. Alethia Biotherapeutics employs patented STAR discovery technology to develop therapeutics that address clinically relevant disease-specific targets, thereby aiding healthcare professionals in managing cancer and its complications.

Leap Medical, Inc. engages in designing, developing, manufacturing, and marketing products that provide the earliest possible indicators of a patient's medical condition. The company is based in Montreal, Canada.

Neuralitic Systems specializes in mobile data intelligence technology, focusing on helping mobile service operators comprehend user behaviors that drive data service adoption. By providing insights into emerging trends and habits, the company enables operators to enhance decision-making related to subscriber acquisition, conversion, and retention. Its solutions are designed to automatically uncover new behavioral patterns, facilitating the dynamic leveraging of these insights to stimulate revenue growth within the data service sector.

Allostera Pharma is a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes.

Neuralitic Systems specializes in mobile data intelligence technology, focusing on helping mobile service operators comprehend user behaviors that drive data service adoption. By providing insights into emerging trends and habits, the company enables operators to enhance decision-making related to subscriber acquisition, conversion, and retention. Its solutions are designed to automatically uncover new behavioral patterns, facilitating the dynamic leveraging of these insights to stimulate revenue growth within the data service sector.

Alethia Biotherapeutics, Inc. is a biotechnology company based in Montreal, Canada, founded in 2002. It specializes in the discovery and development of monoclonal antibody-based therapeutics aimed at treating various forms of cancer, particularly focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. The company's product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the effectiveness of DNA-damaging chemotherapy agents; sCLU, a glycoprotein linked to multiple malignancies; AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases; and AB-0440, a protein involved in osteoclast differentiation associated with bone loss. Alethia Biotherapeutics employs patented STAR discovery technology to develop therapeutics that address clinically relevant disease-specific targets, thereby aiding healthcare professionals in managing cancer and its complications.